NCT01934959

A Trial on Probiotics in Preventing Hirschsprung's Disease Associated Entercolitis

A Prospective Multicenter Randomized Controlled Trial on Probiotics in Preventing Hirschsprung's Disease Associated Entercolitis

• Status: Completed
• Phase: EARLY_Phase 1
• Study type: Interventional
• Enrollment: 60 (actual)
• Sponsor: Tongji Hospital · Academic / Other
• Sex: All
• Age: 1 Month – 13 Years
• Healthy volunteers: Not accepted

Summary

Enterocolitis(EC) is the most common and serious postoperative complication of Hirschsprung's disease(HD) with high morbidity and mortality. Probiotics are live microbes that, when administered in adequate amounts, confer health benefit to the host.Based on this previous knowledge on the beneficial effects of probiotics during pro-inflammatory conditions of the gastrointestinal tract, investigators hypothesized that oral probiotics could decrease the incidence and severity of Hirschsprung's disease associated enterocolitis(HAEC).Investigators conducted a prospective, multicenter, randomized and controlled trial to assess whether oral probiotics could decrease the incidence and severity of Hirschsprung's disease associated enterocolitis(HAEC).

Conditions

• Probiotics
• Hirschsprung's Disease Associated Enterocolitis

Interventions

Type	Name	Description
DRUG	Bifico

Timeline

• Start date: 2008-01-01
• Primary completion: 2010-01-01
• First posted: 2013-09-04
• Last updated: 2013-09-04